文献速递细菌感染、耐药与抗菌药物医院感染防控

吸入阿米卡星辅助静脉标准抗生素治疗机械通气革兰阴性肺炎(INHALE):双盲随机安慰剂对照3期优效性试验

Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
PubMed 文献 · Lancet Infect Dis · 2019-12-19

INHALE为在25国153个ICU开展的双盲随机安慰剂对照3期优效性试验,纳入725例机械通气革兰阴性肺炎患者,比较雾化吸入阿米卡星400mg每12小时一次共10天联合静脉标准抗生素与安慰剂的疗效。

要点

  • 吸入阿米卡星辅助治疗未提高机械通气革兰阴性肺炎患者28-32天生存率。
  • 两组治疗中出现的不良事件和严重不良事件发生率相似。
  • 研究结论不支持在机械通气革兰阴性肺炎患者中使用吸入阿米卡星辅助静脉标准治疗。

核心结论

  • 在机械通气革兰阴性肺炎患者中,吸入阿米卡星辅助静脉标准抗生素治疗未改善28-32天生存率。
  • 研究结果不支持使用吸入阿米卡星作为静脉标准治疗的辅助治疗。

研究设计与样本

  • INHALE为前瞻性、双盲、随机、安慰剂对照、3期优效性研究,包含INHALE 1和INHALE 2两项试验。
  • 研究在25个国家153个医院ICU开展,纳入725例机械通气革兰阴性肺炎患者,随机1:1分配至吸入阿米卡星400mg或雾化生理盐水安慰剂,每12小时一次共10天,均联合静脉标准抗生素。
  • 主要终点为28-32天生存率,在至少接受一剂研究药物、感染革兰阴性病原体且诊断时APACHE II评分≥10的患者中分析(508例)。
  • 安全性分析纳入所有至少接受一剂研究药物的患者(712例)。

主要发现

  • 治疗中出现的不良事件发生率两组相似:阿米卡星组295/353例(84%) vs 安慰剂组303/359例(84%)。
  • 严重治疗中出现的不良事件发生率两组相似:阿米卡星组101例(29%) vs 安慰剂组97例(27%)。

临床怎么用

  • 对于机械通气革兰阴性肺炎患者,不应在静脉标准抗生素治疗基础上常规加用吸入阿米卡星辅助治疗。
  • 临床决策应继续遵循既定指南选择静脉标准抗生素方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment of ventilated pneumonia is often unsuccessful, even when patients are treated according to established guidelines. Therefore, we aimed to investigate the efficacy of the combination drug device Amikacin Inhale as an adjunctive therapy to intravenous standard-of-care antibiotics for pneumonia caused by Gram-negative pathogens in intubated and mechanically ventilated patients. METHODS: INHALE was a prospective, double-blind, randomised, placebo-controlled, phase 3 study comprising two trials (INHALE 1 and INHALE 2) done in 153 hospital intensive-care units in 25 countries. Eligible patients were aged 18 years or older; had pneumonia that had been diagnosed by chest radiography and that was documented as being caused by or showing two risk factors for a Gram-negative, multidrug-resistant pathogen; were intubated and mechanically ventilated; had impaired oxygenation within 48 h before screening; and had a modified Clinical Pulmonary Infection Score of at least 6. Patients were stratified by region and disease severity (according to their Acute Physiology and Chronic Health Evaluation [APACHE] II score) and randomly assigned (1:1) via an interactive voice-recognition system to receive 400 mg amikacin (Amikacin Inhale) or saline placebo, both of which were aerosolised, administered every 12 h for 10 days via the same synchronised inhalation system, and given alongside standard-of-care intravenous antibiotics. All patients and all staff involved in administering devices and monitoring outcomes were masked to treatment assignment. The primary endpoint, survival at days 28-32, was analysed in all patients who received at least one dose of study drug, were infected with a Gram-negative pathogen, and had an APACHE II score of at least 10 at diagnosis. Safety analyses were done in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, numbers NCT01799993 and NCT00805168. FINDINGS: Between April 13, 2013, and April 7, 2017, 807 patients were assessed for eligibility and 725 were randomly assigned to Amikacin Inhale (362 patients) or aerosolised placebo (363 patients). 712 patients received at least one dose of study drug (354 in the Amikacin Inhale group and 358 in the placebo group), although one patient assigned to Amikacin Inhale received placebo in error and was included in the placebo group for safety analyses. 508 patients (255 in the Amikacin Inhale group and 253 in the placebo group) were assessed for the primary endpoint. We found no between-group difference in survival: 191 (75%) patients in the Amikacin Inhale group versus 196 (77%) patients in the placebo group survived until days 28-32 (odds ratio 0·841, 95% CI 0·554-1·277; p=0·43). Similar proportions of patients in the two treatment groups had a treatment-emergent adverse event (295 [84%] of 353 patients in the Amikacin Inhale group vs 303 [84%] of 359 patients in the placebo group) or a serious treatment-emergent adverse event (101 [29%] patients vs 97 [27%] patients). INTERPRETATION: Our findings do not support use of inhaled amikacin adjunctive to standard-of-care intravenous therapy in mechanically ventilated patients with Gram-negative pneumonia. FUNDING: Bayer AG.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis. 2019. PMID: 31866328. doi:10.1016/S1473-3099(19)30574-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。